Drug Trial Radar · NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
May 31, 2023
Primary completion
Jun 2, 2026
Study completion Jun 2, 2026
Sponsor
- Lead sponsor
- Sensei Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- May 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Conditions
- Solid Tumor, Adult
- Advanced Solid Tumor
- Head and Neck Cancer
- Breast Cancer
- Colon Cancer
- Pancreatic Cancer
- Gastric Cancer
- Esophageal Cancer
- Prostate Cancer
- Uterine Cancer
- Cervix Cancer
- Ovarian Cancer
- Kidney Cancer
- Bladder Cancer
- Thyroid Cancer
- Melanoma
- Sarcoma
- Advanced Cancer
- Metastatic Cancer
- Refractory Cancer
- Non Small Cell Lung Cancer
- Merkel Cell Carcinoma
Interventions
SNS-101 (anti-VISTA)Drug
SNS-101 IV every 21 days.
CemiplimabDrug
Cemiplimab IV every 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events - Part A & BTime frame: Day 1 through 90 days after the last dose
- Determine the Recommended Phase 2 dose or maximum tolerated dose - Part A & BTime frame: Approximately 15 months
- Objective Response Rate (ORR) - Part C. Part C was never initiated.Time frame: Day 1 through study completion (approximately 1 year).
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
UCLA Hematology/Oncology
Los Angeles, California
University of Colorado Cancer Center - Anschutz Medical
Aurora, Colorado
Norton Healthcare
Louisville, Kentucky
Henry Ford Cancer
Detroit, Michigan
Icahn School of Medicine at Mt. Sinai
New York, New York
University of Pennsylvania, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Sanford Cancer Center
Sioux Falls, South Dakota
NEXT Oncology Dallas
Irving, Texas
South Texas Accelerated Research Therapeutics (START) San Antonio
San Antonio, Texas
START Mountain Region
West Valley City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.